Stemline talks SL-401, ASH; shares rally


Stemline Therapeutics (STML +11.2%) rallies after saying investigators will give a clinical update of SL-401 in blastic plasmacytoid dendritic cell neoplasm at ASH.

Also on the agenda: Preclinical data for SL-401 in multiple myeloma and chronic eosinophilic leukemia and preclinical data from SL-101 in AML.

The company announces one new BPDCN patient CR and notes that "to date there have been 5 CRs and 1 PR" out of seven evaluable patients for an ORR of 86%. (PR)

Previously: Aegis sees SL-401 peak sales of $800M to $3B.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs